• 1
    The Interferon β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655661.
  • 2
    Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285294.
  • 3
    Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:14981504.
  • 4
    Río J, Nos C, Tintoré M et al. Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002; 52:400406.
  • 5
    Comabella M, Lunemann JD, Rio J et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009; 132:33533365.
  • 6
    Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 1993; 93:16551663.
  • 7
    Axtell RC, de Jong BA, Boniface K et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16:406412.
  • 8
    Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227231.
  • 9
    Río J, Nos C, Tintoré M et al. Defining the response to interferon-beta in relapsing–remitting multiple sclerosis patients. Ann Neurol 2006; 59:344352.
  • 10
    Bonjardim CA, Ferreira PC, Kroon EG. Interferons: signalling, antiviral and viral evasion. Immunol Lett 2009; 29:111.
  • 11
    Le Bon A, Durand V, Kamphuis E et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 2006; 176:46824689.
  • 12
    Lee LF, Axtell R, Tu GH et al. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci Transl Med 2011; 3:93ra68.
  • 13
    Bushnell SE, Zhao Z, Stebbins CC et al. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology 2012; 79:531537.